Home > biosimilars

biosimilars MEMBER ARTICLES

Getting Lost in the Thicket: AbbVie Wields Its Expansive Humira® Patent Portfolio Against Alvotech’s Adalimumab Biosimilar
Rothwell Fig logo 1 | International Network of Boutique and Independent Law Firms

Author: Andrew J. StoraskaPublished: June 24, 2021In the most recent of a series of litigations by AbbVie against manufacturers seeking to market biosimilar versions of Humira®, the world’s most profitable drug, AbbVie initiated an action against Alvotech in the district court for the Northern District of Illinois on April 27, 2021,

Read More
Rothwell Fig, biosimilars, AbbVie
Chinese Patent Linkage, Patent Term Adjustment, and Patent Term Extension Guidelines Unveiled For Comments
Rothwell Fig logo 1 | International Network of Boutique and Independent Law Firms

Author: Xiaoban XinPublished: August 25, 2021On August 3, 2021, the China National Intellectual Property Administration (CNIPA) released the Draft Revised Patent Examination Guidelines (“Draft Guidelines”) for comments.  The revisions in the Draft Guidelines reflect the recently amended Chinese Patent Law that came into effect on June 1, 2021, and the Draft Revised Implementing Regulations (“Draft

Read More
privacy law, Rothwell Fig, Chinese Patent Linkage